archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Symetis announces intention to float on SIX Swiss Exchange
    the Symetis support team The company recorded revenues of CHF 17 9 million in 2014 and CHF 10 8 million in the first half year of 2015 representing a growth rate of 68 in constant currencies compared to the first half year of 2014 The TAVI field is driven by innovation and Symetis has demonstrated its ability to develop and successfully bring unique solutions to market The IPO will provide Symetis with the means and the visibility to go further and faster both on the innovation and commercial fronts with the goal to secure its place among the top TAVI players said Jacques R Essinger CEO of Symetis With market data showing the TAVI market to reach USD 3 billion by 2019 TAVI is poised to become one of the largest segments in the cardiovascular space TAVI A fast growing market TAVI is one of the fastest growing segments in the medical devices sector The size and growth of the TAVI market are driven by a number of factors including a continual increase in the number of patients requiring aortic valve replacement These factors include the high risk associated with open heart surgery for patients of advanced age or who have life threatening co morbidities the reluctance of patients to undergo open heart surgery and the shorter hospital stay and rapid recovery times associated with TAVI relative to traditional surgical aortic valve replacement Over time TAVI procedures are expected to replace an increasing proportion of the traditional open heart surgical repair market About the IPO Symetis will issue primary shares only in the proposed IPO and intends to complete the offering in 2015 The gross proceeds are expected to be approximately CHF 80 million In addition the syndicate banks will be granted a 15 over allotment option The proceeds of the IPO will be used to accelerate commercial expansion in Europe reinforce the R D effort and conduct clinical trials for expansion outside Europe including Japan and the United States Furthermore the proceeds are intended to finance the expansion of manufacturing capacity in the mid term potentially license or acquire synergistic technologies and or products strengthen the balance sheet and for general corporate purposes Symetis existing investors have committed to subscribe to CHF 15 million in any potential equity offering Banking syndicate In preparation for the proposed IPO Credit Suisse AG has been appointed as Global Coordinator and Joint Bookrunner and Jefferies International Limited as Joint Bookrunner Bank am Bellevue AG and Bank Vontobel AG are acting as Co Managers About Symetis Symetis SA is a leading Swiss medical technology company focused on transcatheter aortic valve implantation TAVI The company s products ACURATE TA and ACURATE neo TF and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies Symetis believes that the ACURATE family of products offers superior performance characteristics and is well positioned to target the estimated USD 3 billion TAVI market in

    Original URL path: http://www.endeavourvision.com/news-n264-more-Symetis+announces+intention+to+float+on+.htm (2016-04-25)
    Open archived version from archive


  • CeQur Announces $100 Million Series C Financing
    and commercializing advanced yet simple to use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The Company s fully optimized device PaQ is a three day wearable device that provides freedom from multiple daily insulin injections The Company is headquartered in Lucerne Switzerland with operations in Marlborough Massachusetts and Nordborg Denmark CeQur was established in January 2008 The company is chaired by 34 year J J veteran Eric Milledge and led by a team of highly experienced executives with backgrounds from relevant companies including Becton Dickinson Company J J Novo Nordisk Abbott Roche and Smith Nephew More information can be found at www cequr com About Woodford Investment Management Woodford Investment Management LLP is a fast growing asset management company built on a founding philosophy of transparency and simplicity Launched in May 2014 the company has more than 12bn assets under management Further information can be found at www woodfordfunds com About Arthurian Life Sciences Founded by renowned life sciences entrepreneur Professor Sir Chris Evans Arthurian has an investment team with more than 200 years combined experience having raised over USD 11 billion of investment funds and USD 9 4 billion of co investment Arthurian is a specialist in the life sciences sector It is discretionary fund manager of the Wales Life Sciences Investment Fund LP the Fund The Fund is a strategic investment fund whose cornerstone investor is the Welsh Government It invests globally across the life sciences sector where those investments bring economic benefit to the life sciences sector in Wales About Endeavour Vision Ltd Endeavour is an internationally recognized investor in innovative technologies in particular in medical technologies with more than 60 investments made globally The team combines successful investment professionals and world class industry veterans with extensive experience in the medical device industry in the U S Europe and Asia Endeavour Vision focuses on companies with global ambitions in medical technology and digital health sectors in Europe and the US helping them to accelerate their global growth and market leadership For more information about Endeavour and its portfolio please visit www endeavourvision com About Schroders plc Schroders is a global asset management company with CHF 455 6 billion assets under management as of 30 June 2015 The asset manager s clients are major financial institutions including pension funds banks and insurance companies local and public authorities governments charities high net worth individuals and retail investors Schroders has developed under stable ownership for over 210 years Schroders has been active in Switzerland since 1967 With CHF 26 4 billion of assets under management and around 260 employees Switzerland is Schroders second most important market outside the UK The Schroders Private Equity department working from the Geneva office has been active since 2007 and currently manages a portfolio of eight direct investments across sectors and geographies About VI Partners VI Partners is a leading Swiss venture capital firm that invests in

    Original URL path: http://www.endeavourvision.com/news-n263-more-CeQur+Announces+%24100+Million+Series+C+.htm (2016-04-25)
    Open archived version from archive

  • Elisabeth Brøndum Jensen - Executive Assistant
    at the Sun Yat Sen University in Guangzhou China Her final Master Thesis was a case study on the Danish luxury retailer Bang Olufsen and their approach to the Chinese market and the rapidly developing Chinese middle class tel 41 22 544 60 33 fax 41 22 544 60 06 cell 41 79 953 71 80 email vcard open vcard Elisabeth is a passionate traveler who loves to explore new cities and cultures Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick They are highly professional partners and support us in every possible manner Christian Lindner Co Founder and CEO Retailo AG We wanted a Venture Capital investor who was

    Original URL path: http://www.endeavourvision.com/team-26-4-Elisabeth+Br%F8ndum+Jensen.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
    to 2 1 million for the fourth quarter of 2013 The year over year increase in revenue was primarily due to higher reimbursable research and development activities primarily for our AstraZeneca collaboration Research and development expenses totaled 8 0 million for the fourth quarter of 2014 compared to 7 4 million for the fourth quarter of 2013 The increase was primarily driven by headcount growth to support the development of BIND s internal pipeline and collaborations General and administrative expenses totaled 4 2 million for the fourth quarter of 2014 compared to 2 7 million for the fourth quarter of 2013 The increase was primarily due to higher compensation expenses and external consulting expenses Net loss for the fourth quarter of 2014 was 8 5 million compared to a net loss of 8 1 million for the fourth quarter of 2013 Full Year 2014 Financial Results Revenue for the year ended December 31 2014 was 10 4 million compared to 10 9 million for the year ended December 31 2013 The year over year decrease in revenue was primarily due to a reduction in up front license fee revenue recognized that was partially offset by an increase in reimbursable research and development activities we performed under our collaboration agreements principally for AstraZeneca Pfizer and Roche Research and development expenses were 28 9 million for the year ended December 31 2014 compared to 24 4 million for the year ended December 31 2013 This increase was primarily driven by headcount growth to support the development of BIND s internal pipeline and collaborations General and administrative expenses were 15 1 million for the year ended December 31 2014 compared to 13 4 million for the year ended December 31 2013 The increase was primarily due to higher compensation expenses external consulting expenses and other expenses principally related to operating as a public company since the fourth quarter of 2013 Net loss for the year ended December 31 2014 was 32 5 million compared to a net loss of 27 7 million for the year ended December 31 2013 Cash cash equivalents and short term investments were approximately 41 million as of December 31 2014 Financial Expectations The Company expects that its cash cash equivalents and short term investments as of December 31 2014 in addition to the capital raised in the first quarter of 2015 through its amended credit facility with Hercules Technology III L P and its February 10 2015 offering of common stock and warrants will fund operating expenses and capital expenditure requirements into mid 2016 This expectation is based on the Company s current operating plans and research and development funding that it expects to receive under its existing collaborations but excludes any potential milestone payments Recent Business Developments On March 10 2015 BIND announced the appointment of Andrew Hirsch as acting president and chief executive officer On February 10 2015 BIND closed a public offering of common stock and warrants with proceeds of approximately 20 million net of

    Original URL path: http://www.endeavourvision.com/news-n250-c72-BIND+Therapeutics+Reports+Fourth+Quarter.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer
    taking on expanded roles gives us a team with the deep experience needed to take BIND to the next level continued Mr Hirsch I am excited about the opportunities in front of us and confident in the team we have in place to achieve them About BIND Therapeutics BIND Therapeutics is a clinical stage nanomedicine platform company developing a pipeline of Accurins its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue BIND is leveraging its Medicinal Nanoengineering platform to develop a pipeline of Accurins targeting hematological and solid tumors and has a number of strategic collaborations with biopharmaceutical companies to develop Accurins in areas of high unmet need BIND s lead drug candidate BIND 014 is a prostate specific membrane antigen PSMA targeted Accurin that contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in development for the treatment of non small cell lung cancer or NSCLC in patients with KRAS mutations or squamous histology In addition BIND plans to initiate clinical trials with BIND 014 in cervical bladder head and neck and cholangio cancers in 2015 BIND is also advancing BIND 510 its second PSMA targeted Accurin drug candidate containing vincristine a potent microtubule inhibitor with dose limiting peripheral neuropathy in its conventional form through important preclinical studies to position it for an Investigational New Drug IND application filing with the U S Food and Drug Administration FDA in 2016 Lastly BIND is developing Accurins designed to inhibit PLK1 and KSP both of which BIND believes are promising anti mitotic targets that have been limited in the clinic due to myelotoxicity prior to reaching therapeutic doses BIND has announced ongoing collaborations with Pfizer Inc AstraZeneca AB F Hoffmann La Roche Ltd and Merck Co or Merck known as Merck Sharp Dohme outside the United States and Canada to develop Accurins based on their proprietary therapeutic payloads and targeting ligands Forward Looking Statements Disclaimer This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 All statements contained in this press release that do not relate to matters of historical fact should be considered forward looking statements including statements regarding our intentions regarding a permanent chief executive officer beliefs that Accurins have the potential to become a major new therapeutic modality goals to gain approval of the first Accurin nanomedicine advance and build BIND s proprietary oncology pipeline and apply BIND s technology in new therapeutic approaches expectations regarding BIND s nanomedicine platform expectations regarding our leadership team and opportunities and financial position These forward looking statements are based on management s current expectations These statements are neither promises nor guarantees but involve known and unknown risks uncertainties and other important factors that may cause our actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by the forward looking statements including but

    Original URL path: http://www.endeavourvision.com/news-n249-c72-BIND+Therapeutics+Appoints+Andrew+Hirsch.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology
    pathways and we look forward to combining compounds from our oncology portfolio with BIND s nanomedicine technology platform Under the terms of the agreement BIND will apply its Medicinal Nanoengineering platform to develop targeted Accurins based initially on Merck supplied investigational KSP and PLK1 inhibitors The agreement also includes the option to incorporate additional Merck compounds in the future BIND will fund and conduct research and development activities to advance Accurin product candidates based on these agents through first in human clinical studies after which Merck and BIND will alternate in choosing whether or not to further develop and commercialize the Accurin products If BIND opts in in most scenarios there will be no payments made to Merck beyond a royalty on future product sales If Merck opts in it will pay BIND a fee based on a multiple of BIND s research and development expenses plus a royalty on future product sales Further terms of the agreement were not disclosed About BIND Therapeutics BIND Therapeutics is a clinical stage nanomedicine platform company developing Accurins its novel targeted therapeutics BIND is leveraging its Medicinal Nanoengineering platform to develop a pipeline of Accurins initially in oncology as well as Accurins in collaboration with biopharmaceutical companies BIND s lead drug candidate BIND 014 is an Accurin that targets PSMA and contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in Phase 2 clinical trials for the treatment of non small cell lung cancer and metastatic castrate resistant prostate cancer BIND has announced ongoing collaborations with Pfizer Inc AstraZeneca AB F Hoffmann La Roche Ltd and Merck Co to develop Accurins based on their proprietary therapeutic payloads and targeting ligands BIND s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women s Hospital Harvard Medical School of BIND s scientific founders Dr Robert Langer and Dr Omid Farokhzad For more information please visit the Company s web site at www bindtherapeutics com BIND Contacts Media The Yates Network Gina Nugent 617 460 3579 gina theyatesnetwork com or Investors Stern Investor Relations Paul Cox 212 362 1200 BIND sternir com Source BIND Therapeutics Inc back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who

    Original URL path: http://www.endeavourvision.com/news-n242-c72-BIND+Therapeutics+Announces+Agreement+wi.htm (2016-04-25)
    Open archived version from archive

  • Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant
    with such large drug companies as Amgen Inc Pfizer Inc and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines Meanwhile Bind Therapeutics is also working on a drug candidate that is being tested as a potential treatment for non small cell lung cancer and metastatic castrate resistant prostate cancer Bind s platform originated from the nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women s Hospital Harvard Medical School by the company s scientific founders and directors Dr Robert Langer and Dr Omid Farokhzad Bind was one of many local life sciences companies to go public last year Others include Enanta Pharmaceuticals Inc and Tetraphase Pharmaceuticals Inc of Watertown and Cambridge based Foundation Medicine Inc Therapeutics Epizyme Inc Bluebird Bio Inc Agios Pharmaceuticals Inc and Acceleron Pharma Inc back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to

    Original URL path: http://www.endeavourvision.com/news-n226-c72-Bind+Therapeutics+enters+nanomedicine+co.htm (2016-04-25)
    Open archived version from archive

  • BIND Therapeutics Announces Pricing of Initial Public Offering
    Cowen and Company LLC c o Broadridge Financial Services Attention Prospectus Department 1155 Long Island Avenue Edgewood NY 11717 Telephone 631 274 2806 Fax 631 254 7140 This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction About BIND Therapeutics BIND Therapeutics is a clinical stage nanomedicine platform company developing Accurins its novel targeted therapeutics BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins initially in oncology as well as Accurins in collaboration with biopharmaceutical companies BIND s lead drug candidate BIND 014 is an Accurin that targets PSMA and contains docetaxel a clinically validated and widely used cancer chemotherapy drug BIND 014 is currently in Phase 2 clinical trials for non small cell lung cancer and metastatic castrate resistant prostate cancer Media contact The Yates Network Gina Nugent 617 460 3579 gina theyatesnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is

    Original URL path: http://www.endeavourvision.com/news-n200-c72-BIND+Therapeutics+Announces+Pricing+of+I.htm (2016-04-25)
    Open archived version from archive



  •